MedTrace Logo

Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial

NCT02997657 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 271

Last updated 2023-03-01

Study results available
· View outcomes & findings →

Summary

Positive Psychotherapy for Smoking Cessation (PPT-S) addresses an array of risk factors for poor smoking outcomes (low positive affect, depressive symptoms, and cynical cognitions), while also providing skills that may buffer against stress and negative affect. The overall objective of this project is to conduct a randomized controlled trial to test the efficacy of PPT-S, enhanced with text messaging, compared to a time-matched behavioral smoking cessation treatment. Participants in both treatment conditions will receive nicotine replacement therapy and a validated text-messaging intervention for smoking cessation that monitors progress in quitting smoking and extends smoking counseling outside of the individual face-to-face context.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Positive Psychotherapy

Exercises designed to boost moods, positive behaviors, and positive cognitions.

BEHAVIORAL

Standard smoking cessation counseling

Counseling designed to provide support and problem solving for smoking cessation

Sponsors & Collaborators

  • Truth Initiative

    collaborator OTHER

  • Brown University

    lead OTHER

Principal Investigators

  • Christopher Kahler, PhD · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2021-11-15
Completion
2021-11-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02997657 on ClinicalTrials.gov